Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment
- 1 October 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (14) , 1889-1897
- https://doi.org/10.1097/00002030-199910010-00011
Abstract
To determine whether highly active antiretroviral therapy (HAART) is effective in HIV-associated neurocognitive impairment.Keywords
This publication has 15 references indexed in Scilit:
- Antiretroviral drugs and the central nervous systemAIDS, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Temporal trends in the incidence of HTV‐1‐related neurologic diseasesNeurology, 1994
- Dementia in AIDS patientsNeurology, 1993
- Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complexAIDS, 1993
- Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trialAnnals of Neurology, 1993
- Epidemiology of human immunodeficiency virus encephalopathy in the United StatesNeurology, 1992
- Neuropsychological Outcome of Zidovudine (AZT) Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1988